Open Access Highly Accessed Open Badges Research

High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients

Nikolaos Tselis1*, Ulf W Tunn2, Georgios Chatzikonstantinou1, Natasa Milickovic3, Dimos Baltas3, Markus Ratka1 and Nikolaos Zamboglou1

Author Affiliations

1 Department of Radiation Oncology, Klinikum Offenbach, Starkenburgring 66, 63069, Offenbach, Germany

2 Department of Urology, Klinikum Offenbach, Starkenburgring 66, 63069, Offenbach, Germany

3 Department of Medical Physics and Engineering, Klinikum Offenbach, Starkenburgring 66, 63069, Offenbach, Germany

For all author emails, please log on.

Radiation Oncology 2013, 8:115  doi:10.1186/1748-717X-8-115

Published: 8 May 2013



To report the clinical outcome of high dose rate brachytherapy as sole treatment for clinically localised prostate cancer.


Between March 2004 and January 2008, a total of 351 consecutive patients with clinically localised prostate cancer were treated with transrectal ultrasound guided high dose rate brachytherapy. The prescribed dose was 38.0 Gy in four fractions (two implants of two fractions each of 9.5 Gy with an interval of 14 days between the implants) delivered to an intraoperative transrectal ultrasound real-time defined planning treatment volume. Biochemical failure was defined according to the Phoenix Consensus and toxicity evaluated using the Common Toxicity Criteria for Adverse Events version 3.


The median follow-up time was 59.3 months. The 36 and 60 month biochemical control and metastasis-free survival rates were respectively 98%, 94% and 99%, 98%. Toxicity was scored per event with 4.8% acute Grade 3 genitourinary and no acute Grade 3 gastrointestinal toxicity. Late Grade 3 genitourinary and gastrointestinal toxicity were respectively 3.4% and 1.4%. No instances of Grade 4 or greater acute or late adverse events were reported.


Our results confirm high dose rate brachytherapy as safe and effective monotherapy for clinically organ-confined prostate cancer.

Prostate cancer; Brachytherapy; High dose rate; Iridium; Monotherapy